ScaleReady G-Rex Grant Program

The G-Rex® Grant Program is a $42,000,000 initiative undertaken by ScaleReady, in collaboration with Wilson Wolf, Bio-Techne, and CellReady to benefit the cell and gene-modified cell therapy community. The G-Rex® Grant Program is unique and unlike any other grant program. G-Rex® Grant Recipients will not be burdened with inflexible timelines, bureaucratic constraints, micromanagement, or invasive oversight. The G-Rex® Grant Program is intended to be simple, flexible, and easily accessible from initiation through completion. The G-Rex® Grant Program will be successful due to a partnership based on mutual trust, respect, and understanding. The purpose of the G-Rex® Grant Program is to provide interested academic and commercial institutions engaged in pre-clinical research, process development, and/or cGMP manufacture of cell and gene-modified cell therapies (the “Recipient”) with the devices, reagents, and operational know-how to: 1. Implement a highly efficient G-Rex® based cell manufacturing platform and/or 2. Optimize an existing G-Rex® based cell manufacturing platform quickly and at low cost. To be eligible for the G-Rex® Grant Program, a Recipient must satisfy the following criteria: ▪ Be engaged in research and development of cell and gene-modified cell therapies based on or derived from T cells, NK cells, HSCs, or the like. ▪ Be working towards, or have, an existing Investigational New Drug (IND) application. ▪ Be interested in quickly establishing an optimized cGMP manufacturing process at low cost with minimal investment required.